Reports Q1 revenue $459M, consensus $499.72M. “Our results for the first quarter of 2024 show QIAGEN is on track to achieve the goals that we have set for the year. They also showcase the areas of resilient growth from our strategic investments – particularly with the double-digit sales growth in QuantiFERON, QIAstat-Dx and QIAcuity – as well as our commitment to improving efficiency,” said Thierry Bernard, CEO of Qiagen.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
- Is QGEN a Buy, Before Earnings?
- QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
- QIAGEN N.V. to release results for Q1 2024 and hold webcast
- QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
